Clinical Trial Update: Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) [Phase 1]

View source ↗

Summary

The Phase 1 trial of glypican-3–specific CAR-T cells (GLYCAR) for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Glypican-3 CAR-T cells (glypican-3-specific chimeric antigen receptor T cells)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED